Fig. 1
Screening for neutralization antibodies against SARS-CoV-2 and variants. a Thirteen IgG1 antibodies were synthesized from the OPAL antibody library, and their neutralization effects on SARS-CoV-2 were evaluated using Nluc-SARS-CoV-2 pseudoviruses (SARS-CoV-2pp). b Thirteen (10 µg/mL) antibodies were pre-incubated with WT or variant SARS-CoV-2pp (B.1.617.2 or B.1.1.529/BA.1) for 1 h. After incubation for 1 h, ACE2-expressing cells were infected with SARS-CoV-2 WT and variants. Their effects on neutralization were assessed via luciferase analysis, and cell viability was measured using a WST-based cytotoxicity assay. WT, wild-type; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. *P < 0.05, **P < 0.01, significantly different from control